XML 57 R47.htm IDEA: XBRL DOCUMENT v3.22.2.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2022
Dec. 10, 2021
Dec. 10, 2021
Sep. 30, 2022
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2021
Loss Contingencies [Line Items]                  
Proceeds from issuance of common stock         $ 493,481      
Purchase obligation       $ 582,000 $ 582,000       $ 511,000
Stockholders' equity, reverse stock split     5-for-1            
Number of common stock issued       400,000          
Number of additional shares issued       100          
Harborside [Member]                  
Loss Contingencies [Line Items]                  
Stock issued during period, shares, reverse stock splits     1,000,000            
Stock issued during period, shares, stock splits     200,000            
Revenue     $ 10,000,000            
Shares issued   1,000,000 1,000,000            
Incurred damages   $ 75,000 $ 75,000            
Harborside [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Loss contingency, damages sought, value     33,020,000            
Harborside [Member] | Minimum [Member]                  
Loss Contingencies [Line Items]                  
Loss contingency, damages sought, value     $ 5,020,000            
Conversion Labs Rx Business [Member]                  
Loss Contingencies [Line Items]                  
Stock issued during period, shares, stock splits     200,000            
Conversion Labs Rx Business [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Stock issued during period, shares, stock splits     1,000,000            
Pilaris Laboratories, LLC [Member]                  
Loss Contingencies [Line Items]                  
Finite-lived intangible asset, useful life               10 years  
Percentage of net income               10.00%  
Share based compensation arrangement by share based payment award, expiration period             10 years    
Pilaris Laboratories, LLC [Member] | CVLB PR [Member]                  
Loss Contingencies [Line Items]                  
Intercompany agreements, description               As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products  
M.ALPHABET, LLC [Member]                  
Loss Contingencies [Line Items]                  
Intercompany agreements, description         The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts were earned or owed as of September 30, 2022        
Percentage for royalty         13.00%        
Share based compensation arrangement by share based payment award, options, grants in period, gross             20,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price             $ 2.50    
M.ALPHABET, LLC [Member] | Common Stock One [Member]                  
Loss Contingencies [Line Items]                  
Share based compensation arrangement by share based payment award, options, grants in period, gross             20,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price             $ 2.50    
Proceeds from issuance of common stock             $ 7,500,000    
M.ALPHABET, LLC [Member] | Common Stock Two [Member]                  
Loss Contingencies [Line Items]                  
Share based compensation arrangement by share based payment award, options, grants in period, gross             20,000    
Proceeds from issuance of common stock             $ 10,000,000    
M.ALPHABET, LLC [Member] | Common Stock Three [Member]                  
Loss Contingencies [Line Items]                  
Share based compensation arrangement by share based payment award, options, grants in period, gross             40,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price             $ 3.75    
Proceeds from issuance of common stock             $ 20,000,000    
Conversion Labs Rx Business [Member] | Harborside [Member]                  
Loss Contingencies [Line Items]                  
Adjustments to additional paid in capital, stock issued, issuance costs     $ 5,000,000            
Conversion Labs Rx Business [Member] | Harborside [Member] | Maximum [Member]                  
Loss Contingencies [Line Items]                  
Adjustments to additional paid in capital, stock issued, issuance costs     $ 5,000,000            
Conversion Labs Rx [Member]                  
Loss Contingencies [Line Items]                  
Contigency contract amount   $ 273,859              
Blair LLC [Member]                  
Loss Contingencies [Line Items]                  
Contigency contract amount $ 1,000,000